Christopher D Fegan
Overview
Explore the profile of Christopher D Fegan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
304
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pepper A, Zucchetto A, Norris K, Tissino E, Polesel J, Soe Z, et al.
Leukemia
. 2021 Jun;
36(1):271-274.
PMID: 34148055
No abstract available.
2.
Boyle E, Williams L, Blaney P, Ashby C, Bauer M, Walker B, et al.
Leukemia
. 2021 Jun;
36(1):221-224.
PMID: 34148053
No abstract available.
3.
Kennedy E, Coulter E, Halliwell E, Profitos-Peleja N, Walsby E, Clark B, et al.
Blood
. 2021 Jan;
137(22):3064-3078.
PMID: 33512408
Chronic lymphocytic leukemia (CLL) remains incurable despite B-cell receptor-targeted inhibitors revolutionizing treatment. This suggests that other signaling molecules are involved in disease escape mechanisms and resistance. Toll-like receptor 9 (TLR9)...
4.
Lewis T, Corcoran D, Thurston D, Giles P, Ashelford K, Walsby E, et al.
Haematologica
. 2020 May;
106(4):958-967.
PMID: 32381576
Chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are incurable hematological malignancies that are pathologically linked with aberrant NF-κB activation. In this study, we identified a group of novel C8-linked...
5.
Danilov A, Herbaux C, Walter H, Hillmen P, Rule S, Kio E, et al.
Clin Cancer Res
. 2020 Mar;
26(12):2810-2818.
PMID: 32156743
Purpose: Bruton tyrosine kinase (BTK) inhibition alone leads to incomplete responses in chronic lymphocytic leukemia (CLL). Combination therapy may reduce activation of escape pathways and deepen responses. This open-label, phase...
6.
Cohen J, Rossi F, Zucchetto A, Bomben R, Terzi-di-Bergamo L, Rabe K, et al.
Haematologica
. 2019 Oct;
105(6):1613-1620.
PMID: 31582547
We present a laboratory-based prognostic calculator (designated CRO score) to risk stratify treatment-free survival in early stage (Rai 0) chronic lymphocytic leukemia (CLL) developed using a training-validation model in a...
7.
Norris K, Hillmen P, Rawstron A, Hills R, Baird D, Fegan C, et al.
Leukemia
. 2019 Feb;
33(8):1953-1963.
PMID: 30700843
We have previously shown that dividing patients with CLL into those with telomeres inside the fusogenic range (TL-IFR) and outside the fusogenic range (TL-OFR) is powerful prognostic tool. Here, we...
8.
Darvall K, Sam R, Adam D, Silverman S, Fegan C, Bradbury A
J Vasc Surg
. 2009 Mar;
49(5):1235-41.
PMID: 19307088
Background: Uncontrolled studies suggest that patients with chronic venous ulceration (CVU) have an increased prevalence of thrombophilia, similar to that observed in patients with deep vein thrombosis. This study compared...
9.
Auer R, Dighiero G, Goldin L, Syndercombe-Court D, Jones C, McElwaine S, et al.
Br J Haematol
. 2006 Nov;
136(1):73-9.
PMID: 17116127
Chronic lymphocytic leukaemia (CLL) has a strong hereditary component, but an understanding of predisposition genes is poor. Anticipation with familial CLL has been reported, although the molecular mechanism is unknown....
10.
Pepper C, Hambly R, Fegan C, Delavault P, Thurston D
Cancer Res
. 2004 Sep;
64(18):6750-5.
PMID: 15374993
SJG-136 (NSC 694501) is a novel DNA cross-linking agent that binds in a sequence-selective manner in the minor groove of the DNA helix. It is structurally novel compared with other...